Efficacy of Dupilumab in Children 6 Months to 11 Years Old With Atopic Dermatitis: A Retrospective Real-World Study in China

Effectiveness and Safety of Dupilumab in Children Under 6 Years of Age with Moderate-to-Severe Atopic Dermatitis: A Retrospective Real-World Study

“…The objective of vIGA 0-1 was reached by 95.2% at w24 and by 90.5% of patients at w40. The group of children younger than 6 years obtained faster responses than the older children [8]. These results were superior to those observed in our series (74% and 75% of vIGA 0-1 achievement at weeks 16 and 48, respectively).…”

“…Although the results of both series are not directly comparable, it is likely that a higher severity of the patients included in our study (median EASI 25 vs. 21.3, previous use of oral immunosuppressants 94.7% vs. 3.5%) has contributed to these differences. Furthermore, dupilumab doses were higher in the study by Yang et al [8], since the 200 mg dose was administered every 2 weeks and not every 4 weeks as in our study. It would be interesting to continue exploring the best dosing of the drug, especially considering that higher doses have apparently not been associated with a higher frequency of adverse effects in these series [8].…”

“…We found greater effectiveness than seen in clinical trials [6], but in line with other real-life studies. Yang et al [8] included in their retrospective series 21 patients within this age group followed for 40 weeks. The objective of vIGA 0-1 was reached by 95.2% at w24 and by 90.5% of patients at w40.…”

“…There are real-life studies that enroll a good proportion of patients aged 6-12 years with a more than 1-year follow-up [15,19]. Conversely, data beyond 40 weeks in children under 6 years of age are very scarce [8], although this is a population in which long-term follow-up could be of particular relevance. Further studies will be needed in the coming years to determine the best strategy for long-term disease control with dupilumab: in which patients its administration could be spaced, when this could be done, and, most importantly, how long the drug should be maintained are key questions that remain to be answered.…”

Dupilumab Improves Clinical Scores in Pediatric Patients Aged 2 to <18 Years with Uncontrolled Atopic Dermatitis: A Single‐Center, Real‐World Study

“…Notably, the SCORAD, NRS, CDLQI, and POEM were also signifcantly improved, which refects the dupiluamb beneft in aspects of patient-oriented disease burden, including daily pruritus, sleep disorder, school performance, and others. Diferent from other studies which showed no further improvement in EASI scores after W8 until W24 [11], and after 1 month until 6 months [12], respectively, our study revealed signifcant continued improvement in clinical scores from W10 to W16. One possible reason is that our study had higher baseline EASI scores (29.0 ± 16.2) compared to the other two studies (19.6 ± 13.9 and 19.23 ± 3.03), suggesting the necessity of completing the treatment until W16 for pediatric AD patients, at least for those with more severe eczematous lesions.…”